{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T07:52:28Z","timestamp":1678953148478},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.3816\/clm.2009.n.043","type":"journal-article","created":{"date-parts":[[2009,6,17]],"date-time":"2009-06-17T04:27:43Z","timestamp":1245212863000},"page":"217-222","source":"Crossref","is-referenced-by-count":1,"title":["Response Dynamics in Chronic-Phase Chronic Myeloid Leukemia"],"prefix":"10.3816","volume":"9","author":[{"given":"Michael J.","family":"Mauro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2009.n.043_bib1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/shem.2003.50042","article-title":"The cytogenetic response as a surrogate marker of survival","volume":"40","author":"Rosti","year":"2003","journal-title":"Semin Hematol"},{"key":"10.3816\/CLM.2009.n.043_bib2","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/cncr.11223","article-title":"Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis","volume":"97","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.n.043_bib3","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":"Favorable long-term follow-up results over six years for response, survival and safety with imatinib mesylate therapy in chronic phase chronic myeloid leukemia post failure of interferon-alpha treatment","volume":"111","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.043_bib4","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.n.043_bib5","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2006-02-001495","article-title":"Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials","volume":"108","author":"Roy","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.043_bib6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1056\/NEJM199707243370402","article-title":"Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group","volume":"337","author":"Guilhot","year":"1997","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.n.043_bib7","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood.V99.5.1527","article-title":"A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia","volume":"99","author":"Baccarani","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.043_bib8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7326\/0003-4819-122-4-199502150-00003","article-title":"Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service","volume":"122","author":"Kantarjian","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.3816\/CLM.2009.n.043_bib9","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/S0140-6736(95)92596-1","volume":"345","author":"Allan","year":"1995","journal-title":"Lancet"},{"key":"10.3816\/CLM.2009.n.043_bib10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1200\/JCO.1999.17.1.284","article-title":"Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine","volume":"17","author":"Kantarjian","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.043_bib11","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.n.043_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.V110.11.25.25","article-title":"IRIS 6-year follow-up: sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"110","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.043_bib13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.V110.11.27.27","article-title":"Time to complete cytogenetic response (CCyR) does not affect long-term outcomes for patients on imatinib therapy","volume":"110","author":"Guilhot","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.043_bib14","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemianet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.043_bib15","author":"National Comprehensive Cancer Network"},{"key":"10.3816\/CLM.2009.n.043_bib16","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.n.043_bib17","first-page":"513","volume":"91","author":"Gratwohl","year":"2006","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.n.043_bib18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3109\/10428190109057985","article-title":"Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase","volume":"41","author":"Giles","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2009.n.043_bib19","first-page":"182a","article-title":"Probability and impact of obtaining a cytogenetic response to imatinib as initial therapy for chronic myeloid leukemia in chronic phase","volume":"102","author":"Druker","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.043_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.V106.11.1089.1089","article-title":"Five year follow-up results of a phase II trial in patients with late chronic phase (L-CP) chronic myeloid leukemia (CML) treated with imatinib who are refractory\/intolerant of interferon-alpha","volume":"106","author":"Gambacorti","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.043_bib21","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2005.03.2011","article-title":"Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment","volume":"24","author":"Iacobucci","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.043_bib22","doi-asserted-by":"crossref","first-page":"613a","DOI":"10.1182\/blood.V108.11.432.432","article-title":"Delayed achievement of molecular responses is associated with increased risk of progression among patients with chronic myelogenous leukemia in chronic phase treated with imatinib","volume":"108","author":"Quintas-Cardama","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.043_bib23","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/sj.leu.2403664","article-title":"Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse","volume":"19","author":"Marin","year":"2005","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.n.043_bib24","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2002-05-1451","article-title":"Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia","volume":"101","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.043_bib25","first-page":"2092","article-title":"The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment","volume":"9","author":"Zonder","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.n.043_bib26","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood-2003-06-2042","article-title":"Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses","volume":"102","author":"Marin","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.043_bib27","first-page":"317a","article-title":"Imatinib dose escalation is effective in patients with chronic myeloid leukemia in chronic phase","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.043_bib28","doi-asserted-by":"crossref","first-page":"313a","DOI":"10.1182\/blood.V110.11.1035.1035","article-title":"Impact of imatinib mesylate dose escalation on resistance and sub-optimal responses to standard-dose therapy in patients with chronic myeloid leukemia","volume":"110","author":"Jabbour","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.043_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.V110.11.734.734","article-title":"Efficacy of dasatinib in patients with chronic-phase chronic myelogenous leukemia with resistance or intolerance to imatinib: 2-year follow-up data from START-C (CA180-013)","volume":"110","author":"Stone","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.043_bib30","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.043_bib31","first-page":"1","article-title":"Comparison of dasatinib to high-dose imatinib in patients who experience imatinib failure: results from a randomized, phase-II trial (CA180017, START-R)","volume":"92","author":"Martinelli","year":"2007","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.n.043_bib32","doi-asserted-by":"crossref","first-page":"226a","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia patients with imatinib-resistance or intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.043_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.V106.11.166.166","article-title":"Beneficial effects of cytogenetic and molecular response on long-term outcome in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM): update from the Iris Study","volume":"106","author":"Simonsson","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.043_bib34","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood-2007-09-110189","article-title":"Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods","volume":"111","author":"Kantarjian","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.043_bib35","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1038\/sj.leu.2403158","article-title":"Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"17","author":"Branford","year":"2003","journal-title":"Leukemia"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011701950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011701950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T19:58:58Z","timestamp":1589918338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011701950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S1557919011701950"],"URL":"https:\/\/doi.org\/10.3816\/clm.2009.n.043","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}